Pharma
Fredun Pharmaceuticals Ltd
FREDUN · BSE ·Monday, 26 Oct 20263:16 pm
Market Cap₹2,328 Cr
P/E49.5
P/B8.1
EPS₹27.53
Div Yield0.0%
ROE15.7%
ROCE13.6%
ROE15.7%
1Y Return+84.39%
Avg. Volume0.0M
Price Chart
52-Week Range
About
Fredun Pharmaceuticals Ltd is a Pharma company listed on BSE.
Technicals
Free account
Register freeTechnicals
Create a free account to view momentum, moving averages, and delivery signals.
Quant
Premium
UpgradeQuant metrics
Upgrade to view volatility, drawdown, factor, and risk metrics.
Key Ratios
Market Cap₹2,328 Cr
Current Price₹1,363
52W High / Low₹1,666.4 / ₹454.05
Stock P/E49.5
Price to Book8.1
EPS (TTM)₹27.53
Dividend Yield0.0%
ROE15.7%
1Y Return+84.39%
Day Change-0.37%
Profit & Loss
| Period | TTM | FY26 | FY25 | FY24 | FY23 |
|---|---|---|---|---|---|
| Sales | ₹748 Cr | ₹635 Cr | ₹454 Cr | ||
| Expenses | ₹637 Cr | ₹545 Cr | ₹401 Cr | ||
| Operating Profit | ₹110 Cr | ₹91 Cr | ₹52 Cr | ||
| OPM % | 15.0% | 14.0% | 12.0% | ||
| Other Income | ₹0 Cr | ₹4 Cr | ₹2 Cr | ||
| Depreciation | ₹10 Cr | ₹8 Cr | ₹5 Cr | ||
| Interest | ₹41 Cr | ₹39 Cr | ₹22 Cr | ||
| Profit Before Tax | ₹59 Cr | ₹47 Cr | ₹27 Cr | ||
| Tax | ₹15 Cr | ₹14 Cr | ₹7 Cr | ||
| Net Profit | ₹44 Cr | ₹33 Cr | ₹20 Cr | ||
| EPS (₹) | 27.7 | 19.9 | 13.9 | ||
| Dividend Payout % | — | 1% | 2% |
Financial history locked
Register freeRegister free to see 2 more years.
Quarterly Results
| Quarter | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Sep 2024 |
|---|---|---|---|---|---|---|---|
| Sales | ₹228 Cr | ₹213 Cr | ₹161 Cr | ₹145 Cr | |||
| Expenses | ₹196 Cr | ₹184 Cr | ₹135 Cr | ₹123 Cr | |||
| Operating Profit | ₹33 Cr | ₹29 Cr | ₹26 Cr | ₹22 Cr | |||
| OPM % | 14.0% | 14.0% | 16.0% | 15.0% | |||
| Depreciation | ₹4 Cr | ₹3 Cr | ₹2 Cr | ₹2 Cr | |||
| Interest | ₹9 Cr | ₹14 Cr | ₹11 Cr | ₹8 Cr | |||
| Net Profit | ₹13 Cr | ₹11 Cr | ₹10 Cr | ₹9 Cr | |||
| EPS (₹) | 8.0 | 6.6 | 6.5 | 6.6 |
Quarterly history locked
Register freeRegister free to see 3 more quarters.
Balance Sheet
| Period | FY26 | FY25 | FY24 | FY23 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Liabilities | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Equity Capital | ₹5 Cr | ₹5 Cr | ₹5 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Reserves | ₹273 Cr | ₹137 Cr | ₹117 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Borrowings | ₹222 Cr | ₹167 Cr | ₹106 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Other Liabilities | ₹142 Cr | ₹178 Cr | ₹81 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total Liabilities | ₹642 Cr | ₹487 Cr | ₹308 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Assets | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Fixed Assets | ₹118 Cr | ₹53 Cr | ₹48 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Investments | ₹2 Cr | ₹2 Cr | ₹1 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Receivables | — | — | ₹65 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Inventory | — | — | ₹175 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Cash & Equivalents | — | — | ₹1 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Other Assets | ₹522 Cr | ₹433 Cr | ₹18 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total Assets | ₹642 Cr | ₹487 Cr | ₹308 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Balance sheet history locked
Register freeRegister free to see 2 more years.
Cash Flow
| Period | Operating | Investing | Financing | Net Cash Flow |
|---|---|---|---|---|
| FY26 | ₹12 Cr | ₹-74 Cr | ₹121 Cr | ₹60 Cr |
| FY25 | ₹-17 Cr | ₹-6 Cr | ₹27 Cr | ₹4 Cr |
| FY24 | ₹-0 Cr | ₹-8 Cr | ₹6 Cr | ₹-2 Cr |
| FY23 |
Cash flow history locked
Register freeRegister free to see 2 more years.
Peer Comparison
| Company | M.Cap | P/E | ROE | 1Y Return |
|---|---|---|---|---|
| 3B BlackBio Dx Ltd | ₹1,210 Cr | 21.4 | +20.2% | +17.9% |
| Aarey Drugs & Pharmaceuticals Ltd | ₹353 Cr | 75.3 | +2.75% | +59.84% |
| Aarti Drugs Ltd | ₹3,429 Cr | 18.0 | +13.37% | +11.57% |
| Aarti Pharmalabs Ltd | ₹7,495 Cr | 35.2 | +8.51% | +14.26% |
| Abbott India Ltd | — | — | +34.46% | -7.16% |
Mutual Fund Holdings
Free account
Register freeMutual fund holdings
Create a free account to see institutional ownership snapshots.
Bulk & Block Deals
Free account
Register freeBulk & block deals
Create a free account to view recent institutional deal activity.
Analyst Estimates
Free account
Register freeAnalyst estimates
Create a free account to view analyst estimate summaries.
Latest News
2026-10-23Announcement under Regulation 30 (LODR)-AllotmentBSE Filing2026-08-15Fredun Pharmaceuticals Ltd (BOM:539730) (Q1 2027) Earnings Call Highlights: Record 90% Revenue ...GuruFocus.com2026-06-12Fredun Pharmaceuticals Ltd (BOM:539730) Q4 2026 Earnings Call Highlights: Robust Growth and ...GuruFocus.com
Documents & Filings
rupiya.io is for research and education only. Metrics shown are not investment advice. Validate with SEBI-regulated disclosures before acting.